Hermetica Superfood Encyclopedia
Yokukansan is a traditional Japanese kampo formula containing seven herbs that modulates GABA and glutamate neurotransmitter systems to reduce anxiety and agitation. The formula's primary bioactive compounds include glycyrrhizin and ginsenosides that work synergistically to calm neural hyperexcitability.


Yokukansan is a traditional Japanese Kampo formula derived from a blend of herbs, including Uncaria and Licorice root. It is typically prepared as a powder or decoction.
Research, including randomized controlled trials, indicates that Yokukansan may help reduce symptoms of anxiety and agitation, particularly in dementia patients. More studies are needed to explore its full potential.

Dosage should be prescribed by a Kampo practitioner. Consult a healthcare provider before use.
Yokukansan (抑肝散) is a traditional Kampo/Chinese herbal formula, not a food, so conventional macronutrient profiling (calories, fat, carbohydrates, protein) is not applicable in standard dietary terms. Its therapeutic value derives entirely from its bioactive compounds across its seven constituent herbs. Typical formulation (per daily dose, ~7.5 g of dried extract granules or ~20–25 g of crude herb decoction): **Constituent Herbs & Key Bioactive Compounds:** 1. **Atractylodes lancea rhizome (Sōjutsu/Cangzhu, ~4.0 g crude):** Atractylodin (~0.3–0.8 mg/g), atractylone, beta-eudesmol; sesquiterpenoids with anti-inflammatory and gastrointestinal-modulating activity. 2. **Poria cocos (Bukuryō/Fuling, ~4.0 g crude):** Pachymic acid (~0.5–2.0 mg/g), triterpenoids (dehydropachymic acid, tumulosic acid), polysaccharides (beta-glucans, ~2–5% w/w); supports mild diuretic and immunomodulatory effects. Provides trace potassium and magnesium. 3. **Cnidium officinale rhizome (Senkyū/Chuanxiong, ~3.0 g crude):** Ligustilide (~5–15 mg/g, primary phthalide), senkyunolide A (~1–3 mg/g), ferulic acid (~0.5–1.5 mg/g); these phthalides and phenolic acids promote cerebral vasodilation and exhibit antioxidant properties. Ferulic acid bioavailability is relatively high (~40–60% oral absorption). 4. **Angelica acutiloba root (Tōki/Danggui, ~3.0 g crude):** Z-ligustilide (~3–10 mg/g), ferulic acid (~0.5–2.0 mg/g), polysaccharides (angelica polysaccharides ~3–5% w/w), vitamin B12 (trace, ~0.05–0.2 µg/g), folic acid (trace), iron (trace, ~0.1–0.5 mg/g crude herb). Supports hematopoiesis. Ferulic acid shows good oral bioavailability. 5. **Bupleurum falcatum root (Saiko/Chaihu, ~2.0 g crude):** Saikosaponins a, c, and d (~5–15 mg/g total); triterpenoid saponins with anti-inflammatory, hepatoprotective, and corticosteroid-modulating activity. Saikosaponin a is converted by gut microbiota, with bioavailability estimated at ~10–20%. 6. **Glycyrrhiza uralensis root (Kanzō/Gancao, ~1.5 g crude):** Glycyrrhizin (~20–40 mg/g), glycyrrhetinic acid (metabolite), liquiritigenin (~1–3 mg/g), isoliquiritigenin (~0.5–2 mg/g); flavonoids with estrogenic, anti-inflammatory, and GABA-A receptor-modulating effects. Glycyrrhizin oral bioavailability is low (~1–5%) but is hydrolyzed to glycyrrhetinic acid by intestinal bacteria with much higher systemic exposure. Contains trace minerals including manganese and zinc. 7. **Uncaria rhynchophylla hook (Chōtōkō/Gouteng, ~3.0 g crude):** Geissoschizine methyl ether (GM, ~0.5–2.0 mg/g) — a key indole alkaloid acting as a partial agonist at serotonin 5-HT1A receptors and antagonist at 5-HT2A, 5-HT2C, and dopamine D2 receptors; rhynchophylline (~2–6 mg/g), isorhynchophylline (~1–4 mg/g), hirsutine (~0.5–2 mg/g); oxindole and indole alkaloids with neuroprotective, anti-glutamatergic, and calcium channel-blocking activity. GM bioavailability is moderate and considered the primary active constituent for neuropsychiatric effects. **Mineral & Micronutrient Traces (aggregate, approximate per daily dose):** Potassium: ~15–40 mg; Calcium: ~10–30 mg; Magnesium: ~5–15 mg; Iron: ~1–3 mg; Zinc: ~0.2–0.8 mg; Manganese: ~0.3–1.0 mg. **Fiber/Polysaccharides:** Total soluble polysaccharides from Poria, Angelica, and Atractylodes contribute approximately 200–500 mg per daily dose, with prebiotic-like effects on gut microbiota. **Bioavailability Notes:** Many active compounds (saikosaponins, glycyrrhizin, oxindole alkaloids) undergo extensive first-pass hepatic metabolism and gut microbial biotransformation, significantly altering their systemic bioactive profiles. Geissoschizine methyl ether and ferulic acid demonstrate relatively favorable oral bioavailability. Phthalides (ligustilide) are volatile and heat-labile, with bioavailability varying significantly depending on preparation method (decoction vs. granule extract). Co-administration of glycyrrhizin may enhance bioavailability of other constituents through P-glycoprotein and CYP450 modulation.
Yokukansan modulates neurotransmitter balance by enhancing GABAergic inhibition while reducing glutamate excitotoxicity in the brain. Key compounds like glycyrrhizin from licorice and ginsenosides from ginseng cross the blood-brain barrier to regulate calcium channels and reduce neuronal hyperexcitability. The formula also influences serotonin and dopamine pathways through interactions with 5-HT1A receptors and monoamine transporters.
Multiple randomized controlled trials have demonstrated yokukansan's efficacy in reducing behavioral symptoms in dementia patients, with studies showing 30-50% reduction in agitation scores over 4-12 week periods. A systematic review of 12 studies involving over 800 participants found significant improvements in anxiety and sleep quality with typical doses of 7.5g daily. However, most high-quality research focuses on elderly populations with dementia, and evidence for healthy adults remains limited to smaller preliminary studies.
Yokukansan is generally well-tolerated but can cause pseudoaldosteronism due to glycyrrhizin content, leading to elevated blood pressure and hypokalemia with prolonged use. The formula may interact with digoxin, diuretics, and corticosteroids due to licorice root components. Contraindications include severe liver disease, pregnancy, and breastfeeding due to insufficient safety data. Monitoring of blood pressure and electrolytes is recommended during extended use exceeding 8 weeks.